Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice

Gene Therapy

Volumn 6, Issue 10, 1999, Pages 1751-1758

  Chahlavi, A ^a   Rabkin, S D ^a   Todo, T ^a   Sundaresan, P ^a   Martuza, R L ^a,b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer therapy; Herpes simplex virus; HSV seropositive; Multiple treatment; Replication competent

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER THERAPY; COLON CARCINOMA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPES SIMPLEX VIRUS 1; IMMUNE RESPONSE; IMMUNOCOMPETENCE; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; VIRUS MUTANT;

ANIMALS; ANTIBODIES, VIRAL; FEMALE; GENE THERAPY; GENETIC VECTORS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; IMMUNIZATION; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MICE; MICE, INBRED A; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; RANDOM ALLOCATION; TUMOR CELLS, CULTURED;

EID: 0032844251     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301003     Document Type: Article

References (55)

1. Whitley RJ. Herpes simplex viruses. In: Fields BN, Knipe DM, Howley PM (eds). Fields Virology, third edition, vol. 2. Lippincott-Raven: Philadelphia, 1996, pp 2297-2342.
2. Mester JC, Rouse BT. The mouse model and understanding immunity to herpes simplex virus. Rev Infect Dis 1991; 13: S935-S945.
3. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988; 158: 602-614.
4. Burke RL. Contemporary approaches to vaccination against herpes simplex virus. Curr Top Microbiol Immunol 1992; 179: 137-158.
5. McDermott MR et al. Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2. J Virol 1984; 51: 747-753.
6. Halford WT, Veress LA, Gebhardt BM, Carr DJJ. Innate and acquired immunity to herpes simplex virus type 1. Virology 1997; 236: 328-337.
7. Walker J, Leib DA. Protection from primary infection and establishment of latency by vaccination with a herpes simplex virus type 1 recombinant deficient in the virion host shutoff (vhs) function. Vaccine 1998; 16: 1-5.
8. Corey L, Reeves WC, Holmes KK. Cellular immune response in genital herpes simplex virus infection. New Engl J Med 1978; 299: 986-991.
9. Ashley R, Benedetti J, Corey L. Humoral immune response to HSV-1 and HSV-2 viral proteins in patients with primary genital herpes. J Med Viral 1985; 17: 153-166.
10. Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis 1998; 26: 541-553.
11. Eberle R, Mou SW, Zaia JA. The immune response to herpes simplex virus: comparison of the specificity and relative titers of serum antibodies directed against viral polypeptides following primary herpes simplex virus type 1 infections. J Med Virol 1985; 16: 147-162.
12. Buchman TG, Roizman B, Nahmias AJ. Demonstration of exogenous genital reinfection with herpes simplex virus type 2 by restriction endonuclease fingerprinting of viral DNA. J Infect Dis 1979; 140: 295-304.
13. Lodmell DL, Niwa A, Hayashi K, Notkins AL. Prevention of cell-to-cell spread of herpes simplex virus by leukocytes. J Exp Med 1973; 137: 706-720.
14. Lopez C, Arvin AM, Ashley R. Immunity to herpesvirus infections in humans. In: Roizman B, Whitley RJ, Lopez C (eds). The Human Herpesviruses. Raven: New York, 1993, pp 397-425.
15. Mineta T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med 1995; 1: 938-943.
16. Yazaki T, Manz HJ, Rabkin SD, Martuza RL. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 1995; 55: 4752-4756.
17. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 1998; 9. 2777-2185.
18. Toda M, Rabkin SD, Kojima H, Martuza L. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-rumor immunity. Hum Gene Ther 1999; 10: 385-393.
19. Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 34.5, a gene nonessential for growth in culture. Science 1990; 250: 1262-1266.
20. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleortde reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 1acZ insertion mutant. J Virol 1988; 62: 196-205.
21. Nguyen LH, Knipe DM, Finberg RW. Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J Virol 1992; 66: 7067-7072.
22. Morrison LA, Knipe DM. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1. Virology 1997; 239: 315-326.
23. Morrison LA, Knipe DM. Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J Virol 1994; 68: 689-696.
24. Knoblich A, Gortz J, Harle-Grupp V, Falke D. Kinetics and genetics of herpes simplex virus-induced antibody formation in mice. Infect Immun 1983; 39: 15-23.
25. Kahlon J, Lakeman FD, Ackermann M, Whitley RJ. Human antibody response to herpes simplex virus-specific polypeptides after primary and recurrent infection. J Clin Microbiol 1986; 23: 725-730.
26. Zawatzky R, Hilfenhaus J, Marcucci F, Kirchner H. Experimental infection of inbred mice with herpes simplex virus type 1. I. Investigation of humoral and cellular immunity and of interferon induction. J Gen Virol 1981; 53: 31-38.
27. Lopez C. Genetics of natural resistance to herpes virus infections in mice. Nature 1975; 258: 152-153.
28. Fearon ER et al. Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res 1988; 48: 2975-2980.
29. Plautz GE et al. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 1993; 90: 4645-4649.
30. Toda M, Martuza RL, Kojima H, Rabkin SD. In situ cancer vaccination: a defective IL-12 defective vector/replication-competent herpes simplex virus vector combination induces local and systemic antitumor activity. J Immunol 1998; 160: 4457-4464.
31. Dai Y et al. Cellular and humoral immune response to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405.
32. Pelner L, Fowler GA, Hauts HC. Effects of concurrent infections and their toxins on the course of leukemia. Act Med Scand 1958; 338 (Suppl.): 1-47.
33. Bluming AZ, Ziegler JL. Regression of Burkitt's lymphoma in association with measles infection. Lancet 1971; 2: 105-106.
34. Lindenmann J, Klein P. Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. J Exp Med 1967; 126: 93-108.
35. Sinkovics J, Horvath J. New developments in the virus therapy of cancer: a historical review. Intervirology 1993; 36: 193-214.
36. Kapoor AK, Nash AA, Wildy P. Pathogenesis of herpes simplex virus in B cell suppressed mice: the relative roles of cell-mediated and humoral immunity. J Gen Virol 1982; 61: 127-131.
37. Kapoor AK et al. Pathogenesis of herpes simplex virus in congenitally athymic mice: the relative roles of cell-mediated and humoral immunity. J Gen Virol 1982; 60: 225-233.
38. Mitchell BM, Stevens JG. Neuroinvasive properties of herpes simplex virus type 1 glycoprotein variants are controlled by the immune response. J Immunol 1996; 156: 246-255.
39. Shimeld C, Hill TJ, Blyth WA, Easty DL. Passive immunization protects the mouse eye from damage after herpes simplex virus infection by limiting spread of virus in the nervous system. J Gen Virol 1990; 71: 681-687.
40. Lopez C, O'Reilly RJ. Cell-mediated immune responses in recurrent herpesvirus infections. I. Lymphocyte proliferation assay. J Immunol 1977; 118: 895-902.
41. O'Reilly RJ, Chibbaro A, Anger E, Lopez C. Cell-mediated immune responses in patients with recurrent Herpes Simplex infections. II. Infection-associated deficiency of lymphokine production in patients with recurrent herpes labialis or herpes progenitalis. J Immunol 1977; 118: 1095-1102.
42. Zweerink HJ, Stanton LW. Immune response to herpes simplex virus infections: virus-specific antibodies in sera from patients with recurrent facial infections. Infect Immun 1981; 31: 624-630.
43. Posavad CM, Koelle DM, Corey L. High frequency of CD8+ cytotoxic T-lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes. J Virol 1996; 70: 8165-8168.
44. Engler H, Zawatzky R, Kirchner H, Armerding D. Experimental infection of inbred mice with herpes simplex virus. IV. Comparison of Interferon production and natural killer cell activity in susceptible and resistant adult mice. Arch Virol 1982; 74: 239-247.
45. Brenner GJ, Cohen N, Moynihan JA. Similar immune response to nonlethal infection with herpes simplex virus-1 in sensitive (BALB/c) and resistant (C57BL/6) strains of mice. Ceff Immunol 1994; 157: 510-524.
46. Herrlinger U et al. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Therapy 1998; 5: 809-819.
47. Lopez C et al. Correlation between low natural killing of fibroblasts infected with herpes simplex virus type 1 and susceptibility to herpesvirus infections. J Infect Dis 1983; 147: 1030-1035.
48. Brchm MA, Bonneau RH, Knipe DM, Tevethia SS. Immunization with a replication-deficient mutant of herpes simplex virus type 1 (HSV-1) induces a CD8+ cytotoxic T-lymphocyte response and confers a level of protection comparable to that of wild-type HSV-1. J Virol 1997; 71: 3534-3544.
49. Gathery-Segard H et al. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol 1998; 72: 2388-2397.
50. Juillard V et al. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur J Immunol 1995; 25: 3467-3473.
51. Yang Y, Li Q, Ertl HCJ, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
52. Zabner J et al. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator ot the nasal epithelium of patients with cystic fibrosis. J Clin Invest 1996; 97: 1504-1511.
53. Brattain MG et al. Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res 1980; 40: 2142-2146.
54. Corbett TH, Griswold DPJ, Peckham JC, Schnabel EMJ. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 1975; 35: 2434-2439.
55. Hanfelt JJ. Statistical approaches to experimental design and data analysis of in vito studies. Breast Cancer Res 1997; 46. 279-302.